Fox Chase Cancer Center

 

23rd Collaborative Group of the Americas on Inherited Colorectal Cancer Annual Meeting
Avatar

GI Cancer Risks Associated with Pathogenic Variants (PV) in the Ataxia Telangiectasia Mutated (ATM) Gene

By 23rd Collaborative Group of the Americas on Inherited Colorectal Cancer Annual Meeting FEATURING Michael Hall
By 23rd Collaborative Group of the Americas on Inherited Colorectal Cancer Annual Meeting FEATURING Michael Hall
18 views
December 10, 2019
0 Comments
Login to view comments. Click here to Login

Featured Video

20:59
Exelixis

Primary Analysis and Follow-up Data of a Combination Therapy in 1L a…

Feat. S. Ratnam

Featured Video

20:25
Exelixis

Primary Analysis and Follow-up Data of a Combination Therapy in 1L a…

Feat. S. Ratnam
Videos
04:25
Total Health

LS-SCLC Updates - 2023 ASCO® Direct Philadelphia

Feat. J. Bauman
04:35
Total Health

Chemo vs. Chemo + Pembro in 1L Pleural Mesothelioma - 2023 ASCO® Dir…

Feat. J. Bauman
26:42
Total Health

ADAURA & KEYNOTE-671 Trials: Early Stage NSCLC Updates - 2023 AS…

Feat. J. Bauman
06:11
Insights from 2023 EHA® Annual Meeting

EHA® 2023 Insights: "An Outpatient Model for Teclistamab Step-U…

Feat. A. Varshavsky-Yanovsky
21:34
2023 Texas Lung Cancer Conference Coverage

The Evolving Role of Dual Checkpoint Inhibition in Advanced NSCLC

Feat. H. Borghaei
03:05
ASCO GU 2023 Conference Coverage

ASCO GU 2023 Adjuvant Therapies in Renal Cell Carcinoma: Are New Dat…

Feat. M. Zibelman
13:51
Fox Chase Cancer Center

Adjuvant Treatment of NSCLC: ADAURA in Context

Feat. M. Edelman
09:51
Fox Chase Cancer Center

Influence of 1L Chemo on Survival Outcomes of Patients with Advanced…

Feat. B. Miron
08:35
Fox Chase Cancer Center

2L Treatment of Advanced Gastric Cancer: Moving Towards an Opportuni…

Feat. N. Vijayvergia
19:53
Bladder Cancer Symposium: Update on Medical and Surgical Management for the Urologist

2021 Update on Advanced Urothelial Cancer: Navigating 1L and Beyond …

Feat. E. Plimack
12:36
3rd Annual Atlanta Precision Oncology Symposium

Genotype-Directed Therapy for Advanced NSCLC: Overview of Targeted T…

Feat. H. Borghaei
13:52
3rd Annual Atlanta Precision Oncology Symposium

Targeted Therapy for Advanced NSCLC: Efficacy Analysis of RET, KRAS,…

Feat. H. Borghaei
34:34
UChicago Genetics in Clinical Cancer Care: From Family Reunions to the Frontline of Developmental Therapeutics

Immunology & IO in Lynch Syndrome: Immune System, MSI & Here…

Feat. M. J. Hall
16:08
Fox Chase Cancer Center

Genomic Differentiation of Early-Onset CRC: When Should the Screenin…

Feat. J. Meyer
08:15
2020 ASCO Virtual Direct™ Highlights

2020 Update on Radiation Therapy in Lung Cancer: Is High-Dose Twice-…

Feat. H. Borghaei
10:59
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Targeted Therapy in NSCLC: Is Adjuvant Osimertin…

Feat. H. Borghaei
03:24
Fox Chase Cancer Center

2020 ASCO Update on Advanced RCC: Pembrolizumab + Axitinib vs. Sunit…

Feat. E. Plimack
14:38
CancerGRACE

The Role of IO in Bladder Cancer: Potential Benefits in Neoadjuvant …

Feat. E. Plimack, R. Sedhom
10:57
23rd Collaborative Group of the Americas on Inherited Colorectal Cancer Annual Meeting

GI Cancer Risks Associated with Pathogenic Variants (PV) in the Atax…

Feat. M. Hall
19:10
Fox Chase Updates in Bladder and Kidney Cancer 2019

2019 1st Line Systemic Therapy for Metastatic Urothelial Carcinoma: …

Feat. E. Plimack
14:23
Fox Chase Cancer Center

Front Line Therapy in NSCLC: Immunotherapy vs Immunotherapy + Chemo?

Feat. H. Borghaei
20:36
Fox Chase Cancer Center

I-O/Chemo Combination Therapies in NSCLC

Feat. H. Borghaei
09:14
Fox Chase Cancer Center

Second Line Treatment Options in NSCLC

Feat. H. Borghaei